{"UPDATE 3-Merck, Ridgeback withdraw COVID drug application in EU": 0.5, "10 Dow Stocks Billionaires Are Loading Up On": 0.8, "Merck &amp; Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair": 0.2, "Top 16 Medicine Producing Countries in the World": 0.7, "11 Best Medical\u00a0 Stocks Under $10": 0.9, "Top 30 S&amp;P 500 Stocks by Index Weight": 0.6, "The 7\u00a0Most Undervalued Blue-Chip Stocks to Buy in February 2023": 0.7, "11 Best Medical Stocks Under $10": 0.7, "Top 30 S&P 500 Stocks by Index Weight": 0.6, "The 7 Most Undervalued Blue-Chip Stocks to Buy in February 2023": 0.8, "15 Best Large-Cap Value Stocks To Buy": 0.8, "10 Personalized Medicine Stocks Billionaires Are Loading Up On": 0.9, "Pharmaceutical Lobbying Group Challenges Biden Administration Over Medicare Price Negotiations": 0.2, "Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE": 0.7, "UPDATE 2-Pharmaceutical trade group sues US over Medicare drug price negotiation plans": 0.1, "Merck takes HHS to court over IRA drug pricing rule": 0.2, "Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal": 0.1, "Companies Brace for Supreme Court Ruling That Could Prompt Scrutiny of Diversity Initiatives": 0.4, "Essential Pharma appoints Lee Morley as Non-Executive Director to the Board": 0.5, "Merck Says Keytruda Regimen Fails To Improve Event-Free Survival In Gastric Cancer Patients": 0.1, "Merck's Keytruda fails to meet one main goal in gastric cancer trial": 0.1, "Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma": 0.3, "Merck Completes Acquisition of Prometheus Biosciences, Inc.": 0.8, "Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer": 0.9, "Merck is Collaborating To Help Make Cancer Care More Accessible Worldwide": 0.7, "KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma": 0.8, "Pet Insect Repellent Market Size is projected to reach USD 24.06 Billion by 2030, growing at a CAGR of 6%: Straits Research": 0.5, "Why Are IO Biotech Shares Trading Lower Today": 0.2, "Eli Lilly CEO Joins Other Pharma Execs, Raises Concern Over Medicare Price Negotiations Impacting Drug Development": 0.3, "2 Healthcare Stocks That Could Make You Richer": 0.7, "U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION\u00ae (sugammadex)": 0.6, "One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.": 0.5, "Top 20 Most Profitable Pharmaceutical Companies In The World": 0.7, "Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices": 0.4, "Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023": 0.6, "UPDATE 1-US Chamber of Commerce sues over government's drug pricing power": 0.3, "US Chamber of Commerce sues over government's drug pricing power": 0.3, "U.S. Chamber of Commerce Challenges Federal Government\u2019s New Drug-Price Powers": 0.3, "Four Days Left To Buy Merck &amp; Co., Inc. (NYSE:MRK) Before The Ex-Dividend Date": 0.5, "Merck (MRK) Outpaces Stock Market Gains: What You Should Know": 0.6, "15 Healthcare Stocks Billionaires Are Loading Up On": 0.7, "Merck &amp; Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It": 0.5, "FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer": 0.8, "The 3 Best Defensive Stocks to Buy in June 2023": 0.7, "Drug Maker Merck Sues US Gov. Over Inflation Reduction Act": 0.2, "Dow Jones Today: Index Higher on Bank Bounce": 0.6, "Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts": 0.5, "Merck sues U.S. government over Medicare drug pricing negotiation": 0.2, "Merck Sues To Stop Medicare Drug Negotiation": 0.2, "Stock market today: Dow cuts losses to eke out win as regional banks flex muscles": 0.6, "Merck Challenges U.S. Government\u2019s New Powers to Negotiate Drug Prices": 0.3, "S&amp;P 500 struggles for direction as regional banks rebound, but health care weighs": 0.5, "UPDATE 1-Merck sues US government to halt Medicare drug price negotiation": 0.2, "Merck sues US government to halt Medicare drug price negotiation": 0.2, "U.S. FDA Approves New Indication for Merck\u2019s PREVYMIS\u00ae (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients": 0.8, "Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference": 0.7, "UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data": 0.8, "Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%": 0.9, "Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA": 0.8, "Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data": 0.8, "Merck\u2019s KEYTRUDA\u00ae\u00a0(pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC": 0.9, "KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma": 1, "10 Stocks Jim Cramer Thinks Are Climbing In This Market": 0.8, "3 Undervalued Dow Stocks to Buy Before Wall Street Does": 0.7, "FDA Approves LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)": 1, "7 Dividend Stocks to Buy (and Never Sell)": 0.9, "New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy": 0.2, "3 Innovative Growth Stocks to Buy for Next-Gen Profits": 0.8, "Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years": 0.7, "Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today": 0.2, "KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma": 1, "Investors Heavily Search Merck &amp; Co., Inc. (MRK): Here is What You Need to Know": 0.6, "14 Best Biotech Stocks To Buy According To Hedge Funds": 0.8, "14 Best Healthcare Dividend Stocks to Buy": 0.9, "7 Stocks That Could Be the Next $2 Trillion-Dollar Companies": 0.8, "Merck Announces Third-Quarter 2023 Dividend": 0.6, "Fed Rate Increases Hit Small Businesses the Hardest": 0.2, "3 Undervalued Pharma Stocks to Buy for High Total Returns": 0.7, "Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer": 0.5, "7 Stocks That Are Long Overdue for a Relief Rally": 0.6, "25 Most Prescribed Medication in the World": 0.5, "Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs": 0.7, "Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist": 0.3, "Billionaire Ray Dalio\u2019s Top 12 Dividend Stock Picks": 0.9, "Drugmakers Circle $23 Billion Biotech Argenx Ahead of Key Data": 0.6, "Billionaire Ken Fisher\u2019s Top 15 Dividend Stock Picks": 0.9, "Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting": 0.8, "10 \u201cGreat\u201d Earnings Reports Jim Cramer is Talking About": 0.7, "The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International": 0.6, "3 Penny Stocks That Could Make You a Millionaire by 2025": 0.7, "Top Research Reports for UnitedHealth Group, Merck &amp; Texas Instruments": 0.6, "The 3 Best MedTech Stocks to Watch in May 2023": 0.8, "25 Best Hospitals for Cancer Treatment in the World": 0.8, "FTSE 100 and European markets open higher ahead of BoE rate decision": 0.5, "FTSE 100 and European stocks higher as BoE hikes rates again": 0.6, "15 Biggest Immunotherapy Companies in the World": 0.7, "Merck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities": 0.8, "2 Top Healthcare Stocks Defying the Bear Market": 0.7, "7 Hot Growth Stocks Poised to Triple in 2023": 0.8, "Moderna (MRNA) Q1 Earnings &amp; Sales Top Estimates, Stock Up 2%": 0.7, "Here is What to Know Beyond Why Merck &amp; Co., Inc. (MRK) is a Trending Stock": 0.5, "Moderna beats COVID vaccine sales expectations as deferred revenue rolls in": 0.8, "Insurers Can't Use War Argument: Court Rules in Favor of Merck in $1.4 Billion Cyberattack Coverage Case": 0.7, "Merck: Supporting Colleagues Working With Cancer": 0.6, "Merck to Participate in Bank of America Securities 2023 Healthcare Conference": 0.6, "Merck\u2019s Insurers On the Hook in $1.4 Billion NotPetya Attack, Court Says": 0.6, "UPDATE 1-US FDA panel backs restricted use of AstraZeneca's prostrate cancer drug": 0.5, "US FDA panel backs AstraZeneca's prostrate cancer drug": 0.5, "Update on FDA Advisory Committee Vote on LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer": 0.6, "Merck (MRK) Q1 2023 Earnings Call Transcript": 0.5, "Pharma Stock Roundup: MRK &amp; Others Post Q1 Results, LLY Drug Shines in Obesity Study": 0.6, "Company News for Apr 28, 2023": 0.5, "10 Best May Dividend Stocks To Buy": 0.8, "FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting": 0.2, "Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View": 0.8, "Why Merck Stock Is Trading Higher Today": 0.7, "Drugmakers brace for serious headwinds ahead": 0.2, "Drugmakers scout for deals, ramp up research spending": 0.5, "2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back": 0.5, "Merck has strong quarter even as COVID-19 treatment tumble": 0.7, "Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates": 0.8, "Merck &amp; Co posts first-quarter sales beat, raises guidance": 0.8, "Merck beats first-quarter expectations on Keytruda, Gardasil strength": 0.8, "Merck Announces First-Quarter 2023 Financial Results": 0.5, "Merck earnings better-than-expected on Keytruda, Gardasil strength": 0.8, "Meta Platforms, Hasbro and Comcast rise premarket; First Republic fall": 0.5, "Dow futures rise 190 pts; Meta earnings boost sentiment ahead of GDP release": 0.7, "Amazon.com, Mastercard, drug company earnings: 3 things to watch": 0.5, "The 7 Best Stocks From Schwab\u2019s Dividend ETF": 0.8, "Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut": 0.2, "11 Best Mid-Cap Healthcare Stocks To Buy Now": 0.8, "3 Pharma Stocks That Could See a Surge in Demand in 2023": 0.6, "12 Best Pharma Dividend Stocks To Buy in 2023": 0.8, "Merck (MRK) to Report Q1 Earnings: What's in the Cards?": 0.5, "Merck &amp; Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know": 0.6, "Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for": 0.3, "Merck (MRK) Dips More Than Broader Markets: What You Should Know": 0.3, "Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?": 0.7, "How to Tell Biotech\u2019s Likely Winners From Losers": 0.5, "Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?": 0.7, "Prometheus Biosciences stock soars amid $10.8 billion acquisition deal by Merck": 0.7, "These 3 Nasdaq Stocks Are on Fire Today: Here's Why": 0.7, "Merck/Prometheus: Big Pharma must swallow bigger premiums": 0.5, "Moderna stock plunges following mixed analyst reviews of cancer vaccine data": 0.2, "Stock market today: Dow rides banks to close higher, shrugging off Google wobble": 0.6, "Why Shares of Prometheus Biosciences Are Soaring Monday": 0.7, "S&amp;P 500 climbs as banks shine, but Google-led wobble in tech keeps gains in check": 0.6, "Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial": 0.7, "Merck to take $10.3 billion R&amp;D charge for Prometheus deal this year": 0.5, "Midday movers: Charles Schwab, Enphase Energy, Alphabet and more": 0.5, "Merck agrees to acquire Prometheus Biosciences": 0.7, "U.S. stocks are wobbling as investors await more bank earnings": 0.5, "Big Bank Earnings Won\u2019t Reveal If the Turmoil Is Over. Here\u2019s What Will.": 0.5, "Stocks Nudge Higher, Earnings On Deck, Merck Buys Prometheus, Netflix Axes 'Love Is Blind', Charles Schwab Reports - Five Things To Know": 0.6, "Moderna, Xpeng and Uber rise premarket; State Street falls": 0.5, "Dow futures little changed as investors await corporate earnings": 0.5, "PRESS DIGEST- Wall Street Journal - April 17": 0.5, "UPDATE 1-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return": 0.7, "Moderna, Merck Show Progress Toward Cancer Vaccines": 0.7, "Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer": 0.7, "Moderna Shows Progress Toward Cancer Vaccines": 0.7, "Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA": 0.8, "Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer": 0.9, "CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return": 0.8, "Merck to Acquire Prometheus Biosciences": 0.7, "Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.": 0.7, "Merck in talks to acquire Prometheus Biosciences: report": 0.6, "UPDATE 2-Merck to buy Prometheus Biosciences for about $11 bln": 0.8, "Merck to buy Prometheus Biosciences for about $11 billion": 0.8, "3 Dividend Stocks to Buy for a Recession-Proof Portfolio": 0.5, "Bird Flu Keeps Raging. Some Say Vaccines Are Needed to Stop It.": 0.4, "FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma": 0.8, "Delta Air Lines, Amazon, Stellantis rise premarket; Harley-Davidson falls": 0.5, "Merck Named One of Fortune\u2019s 2023 100 Best Companies to Work For(R)": 0.7, "Joe Biden Plans On Running For Re-Election In 2024, Apple Clocks Highest Decline In Q1 PC Shipments, Fox News Confidential Defamation Lawsuit Settlement: Today's Top Stories": 0.5, "UPDATE 2-Merck, Eisai to discontinue late-stage study for skin cancer": 0.4, "Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)": 0.6, "MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection": 0.7, "Merck: Aiming for Health Equity and Business Success": 0.7, "AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study": 0.7, "UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial": 0.7, "Merck (MRK) Stock Moves -0.04%: What You Should Know": 0.5, "Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron\u2019s 100 Most Sustainable U.S. Companies 2023": 0.8, "Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories": 0.4, "FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer": 0.8, "After Denying Earlier, Pfizer &amp; Merck Marginally Cut Prices For COVID-19 Treatments In China": 0.5, "US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities": 0.4, "3 Top Healthcare Stocks to Buy for April": 0.6, "12 Best Dow Stocks To Buy Right Now": 0.6, "UPDATE 1-Bayer defeats Merck in lawsuit over talc liabilities": 0.4, "Bayer defeats Merck in lawsuit over talc liabilities": 0.4, "FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Padcev\u00ae (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer": 0.8, "OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study": 0.4, "10 Best April Dividend Stocks To Buy": 0.6, "7 Growth Stocks That Are Trading at a Bargain Price": 0.6, "Twitter's Revenue Drops As Advertisers Voice Major Concerns": 0.4, "Starter Stock Portfolio: 15 Safe Stocks To Buy": 0.6, "Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27": 0.6, "11 Best Dow Jones Dividend Stocks According to Hedge Funds": 0.6, "India exempts import tax on pricey rare disease medicines": 0.5, "12 Most Promising Healthcare Stocks According to Analysts": 0.6, "FDA Converts to Full Approval Indication for KEYTRUDA\u00ae (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors": 1, "Stocks trade higher at the open, tech sees gains": 1, "12 Best Diversified Dividend Stocks to Buy Now": 1, "Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients": 1, "Health Rounds: Waiting to remove lymph nodes may improve cancer immunotherapy": 0.5, "KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status": 1, "What Makes Merck &amp; Co. (MRK) A Strong Investment?": 1, "Who Are Pfizer's (PFE) Main Competitors?": 0.5, "Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval": 0.5, "Amplifying the Power of Women in Chemistry": 1, "The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton": 1, "Merck (MRK) Stock Sinks As Market Gains: What You Should Know": 0.2, "7 Healthcare Stocks to Buy for Long-Term Growth and Stability": 1, "14 Best Dividend Aristocrat Stocks To Buy Now": 1, "Top Research Reports for Merck, Intel &amp; MercadoLibre": 1, "7 Defensive Stocks to Buy During This Chaotic Spell": 1, "Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?": 1, "Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study": 0, "Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows": 0, "UPDATE 1-Two new vaccines against bird flu effective in Dutch lab -govt": 1, "Merck\u2019s combination therapy in lung cancer fails a Phase 2 clinical trial": 0, "FedEx, Nvidia and Bumble rise premarket; First Republic,  Credit Suisse fall": 0.5, "Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)": 1, "15 Best Dividend Paying Stocks To Buy Now": 1, "10 Best Psychedelic Stocks to Buy According to Hedge Funds": 1, "Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma": 1, "KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma": 1, "Why OPKO Health Shares Jumped on Wednesday": 1, "OPKO Health's Cancer &amp; Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck": 1, "Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine": 1, "Merck, Opko Health sign deal for experimental Epstein-Barr virus vaccine": 1, "Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept": 1, "Merck to Present at the Barclays 2023 Global Healthcare Conference": 1, "Beat the Dow Jones With This Unstoppable Dividend Stock": "0.8", "Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success": 0.2, "Black Scientists, Innovators and Employees are Key to Merck\u2019s History of Invention and Progress": 1, "Merck Highlights Promising Data From Two Candidates In Heart Diseases": 1, "Alternatives to Popular Cholesterol-Lowering Drug Cut Heart-Attack Risk": 1, "Seagen\u2019s Cancer Therapy Is Making It a Takeover Target": 1, "UPDATE 1-Merck's drug boosts exercise capacity in pulmonary hypertension patients": 1, "Merck\u2019s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy": 1, "Merck's drug boosts exercise capacity in pulmonary hypertension patients": 0.8, "Merck\u2019s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study": 0.7, "Why Big Drugmakers Want to Buy Cancer Biotech Seagen": 0.6, "US FDA Approves Intramuscular Administration for Merck\u2019s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)": 0.9, "6 big deal reports: Microsoft-Activision likely to be greenlit by EU | Pro Recap": 0.5, "Health exec: 'Publicly traded entities don\u2019t necessarily understand clinical culture'": 0.4, "Is Trending Stock Merck &amp; Co., Inc. (MRK) a Buy Now?": "0.5", "UPDATE 1-U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug": 0.5, "Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA\u00ae (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer": 0.6, "Here\u2019s Why Investors Consider Merck &amp; Co. (MRK) a Safe Stock": 0.7, "After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytuda Regime Study In Lung Cancer Patients": 0.8, "Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer": 0.8, "UBS: Moderna's clinical-stage vaccines could drive post-COVID revenues": 0.6, "25 Most Profitable Companies in the World": 0.5, "Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate &amp; Lung Cancer Settings": 0.3, "50 Biggest Public Companies in the World": 0.5, "Pfizer favored over Merck for Seagen acquisition: SVB analyst": 0.6, "Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789": 0.5, "10 Most Promising Psychedelic Stocks According To Analysts": 0.6, "Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ": 0.6, "WSJ: Pfizer in talks with Seagen over purchase worth possibly over $30 billion": 0.6, "Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion": 0.6, "Dow futures trade flat, retail earnings in focus": 0.5, "US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-Related Patents": 0.4, "European Authority Recommends Against Approval For Merck-Ridgeback Biotherapeutics' COVID-19 Pill": 0.2, "UPDATE 1-EU regulator recommends against approval for Merck's COVID pill for adults": 0.2, "Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator\u2019s decision to recommend refusing authorization of their COVID antiviral": 0.3, "Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO\u2122 (Molnupiravir)": 0.4, "Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge": 0.3, "UPDATE 1-Senator Warren urges U.S. patent office to scrutinize Merck's Keytruda": 0.4, "Senator Warren urges U.S. patent office to scrutinize Merck's Keytruda": 0.4, "Merck-Backed Kelun-Biotech Picks Banks for Hong Kong IPO, Sources Say": 0.5, "Moderna falls as waning demand for COVID-19 vaccines hit sales, profit": 0.3, "UPDATE 1-Moderna's combination skin cancer therapy receives FDA's breakthrough tag": 0.6, "Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection": 0.7, "12 Most Profitable Pharmaceutical Stocks Now": 0.6, "10 Best March Dividend Stocks To Buy": 0.6, "Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection": 0.7, "Merck's COVID-19 Treatment Fails To Prevent Infection In Household Exposure": 0.3, "Drug Stocks Often Trade in a Pack, but Not Now. Here Are Leaders and Laggards": 0.5, "UPDATE 2-Merck's COVID pill fails to prevent infection among household members": 0.0, "Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline": 0.9, "Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO\u2122 (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19": 0.5, "Is Most-Watched Stock Merck &amp; Co., Inc. (MRK) Worth Betting on Now?": 0.6, "Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA": 0.7, "3 Large-Cap Biotech Stocks to Hold for the Long Haul": 0.8, "Merck (NYSE:MRK) Is Paying Out A Larger Dividend Than Last Year": 0.7, "U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck\u2019s PREVYMIS\u2122 for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk": 0.8, "Merck Says Keytruda/Chemo Combo Improved Overall Survival Compared To Chemo Alone In Gastric Cancer Settings": 0.8, "Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression": 0.9, "2 Ultra-Safe Dividend Stocks to Buy Right Now": 0.8, "Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium": 0.9, "The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser": 0.8, "2 Market-Beating Dividend Stocks to Buy With $500": 0.8, "Top Stock Reports for Merck, Thermo Fisher Scientific &amp; American Express": 0.8, "BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype": 0.9, "IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer Subtype": 0.2, "Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce": 0.3, "Merck: Women in Science? Absolutely.": 0.9, "Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again": 0.7, "The Petri Dish: Dragonfly loses partnership, Merck hires AI expert for local office": 0.5, "Insurers Say Cyberattack That Hit Merck Was Warlike Act, Not Covered": 0.2, "Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023": 0.8, "12 Dividend Stocks to Buy According to Billionaire Ken Fisher": 0.8, "Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down": 0.8, "Drug companies face COVID cliff in 2023 as sales set to plummet": 0.2, "FOCUS-Drug companies face COVID cliff in 2023 as sales set to plummet": 0.2, "12 Safe Stocks to Buy For Long-Term": 0.8, "Merck Full Year 2022 Earnings: EPS Misses Expectations": 0.3, "AbbVie Q4 Preview: What's in Store?": 0.5, "Why Personalis Shares Are Trading Higher Today": 0.7, "Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients": 0.9, "Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&amp;J's Loss in Talc Lawsuits": 0.5, "Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows": 0.2, "Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma": 0.9, "COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst": 0.5, "Merck, Eli Lilly stocks fall over earnings, outlook concerns": 0.2, "The 7 Most Undervalued Dow Stocks to Buy in February 2023": 0.8, "Merck (MRK) Q4 2022 Earnings Call Transcript": 0.5, "Pharma earnings: COVID \u2018is highly uncertain for this year,\u2019 analyst says": 0.0, "Merck\u2019s COVID-19 pill linked to new virus mutations: Study": 0.0, "Why These 2 Stocks Made the Dow Miss the Market Rally": 0.0, "Merck (MRK) Beats on Q4 Earnings &amp; Sales, 2023 View Disappoints": 0.4, "Merck drops as full-year forecast misses consensus": 0.0, "Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023": 0.4, "Midday movers: Meta Platforms, Align Technology, UnitedHealth Group and more": 0.0, "UPDATE 2-Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter": 0.2, "Merck Stock Slumps As 2023 Profit Outlook Clouds Q4 Earnings Beat": 0.2, "Merck stock falls after quarterly earnings top expectations but profit outlook disappoints": 0.2, "Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter": 0.2, "Merck fourth quarter tops expectations on strong COVID pill sales": 0.4, "Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results": 0.0, "Dow futures flat as Fed hikes 0.25%, Meta surges 19.4% after results": 0.5, "Top 25 Smartest Companies To Buy According To Hedge Funds": 0.8, "Will Keytruda &amp; Gardasil Aid Merck (MRK) Sales in Q4 Earnings?": 0.4, "Why Merck &amp; Co. (MRK) Might Surprise This Earnings Season": 0.4, "3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023": 0.8, "7 Healthcare Stocks That Will Be Big Winners in 2023": 0.8, "15 Undervalued Defensive Stocks For 2023": 0.8, "Is Merck &amp; Co. (MRK) a Long-Term Bet?": 0.5, "Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.73": 0.8, "FDA Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a \u22654 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)": 0.8, "The 3 Best Biotech Stocks Under $1 to Buy for January": 0.8, "Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release": 0.5, "2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years": 0.8, "Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs": 0.8, "Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility": 0.0, "Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial": 0.8, "Want to Collect a Dividend Every Month? Buy These 3 High-Yielding Stocks": 0.8, "Merck Announces Second-Quarter 2023 Dividend": 0.0, "Do You Think Merck &amp; Co. (MRK) is an Attractive Investment?": 0.5, "Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference": 0.0, "UPDATE 1-Sinopharm unit gets OK for clinical trials of mRNA COVID vaccine": 0.0, "Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort": 0.8, "Merck set to remove cancer-causing chemical from top diabetes drugs - Bloomberg News": 0.5, "12 Best DRIP Stocks To Own": 0.8, "Why Biotech Is Poised for a Recovery This Year": 0.8, "12 Cheap Monthly Dividend Stocks To Buy": 0.8, "Johnson &amp; Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot": 0.0, "Merck Named One of America\u2019s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech": 0.9, "J&amp;J Slashes Production of Its Unpopular Covid-19 Shot": 0.0, "China\u2019s Shortage of Antivirals Puts Vulnerable People at Risk": 0.0, "7 Hot Healthcare Stocks to Watch in 2023": 0.8, "FAA Technology Glitch Hits US Flights Operations, Coca-Cola &amp; PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories": 0.0, "Merck, Pfizer Rebuts China's Request For Further Price Cuts For COVID-19 Drugs": 0.0, "Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.": 0.5, "The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed": 0.5, "Mormon Church\u2019s 15 Biggest Stock Positions": 0.5, "Top Analyst Reports for Home Depot, Merck &amp; Bank of America": 0.5, "Why Merck (MRK) is a Top Value Stock for the Long-Term": 0.8, "5 Top Pharma Stocks of 2022 to Buy for the Long Haul": 0.8, "How Merck Is Prioritizing Diversity in Clinical Trials and Why It's So Important": 0.7, "Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2": 0.5, "Why investors should stop fixating on Apple and Tesla stock in 2023: Morning Brief": 0.5, "3 Top Stocks of 2022 That Will Shine Again in 2023": 0.7, "Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference": 0.5, "Merck &amp; Co., Inc. (NYSE:MRK) insiders sold US$3.0m worth of stock, possibly signalling a downtrend": 0.2, "Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks": 0.5, "COVID-related ICU patients rise to 5-month high above 5,000\u2014are new cases really falling?": 0.0, "Merck Rallies to Best Year Since 1995 on Strong Sales, Drug Data": 0.8, "Dow Jones Beats S&amp;P 500 in 2022: 5 Hot Stocks": 0.7, "Dow, Nasdaq, and S&amp;P 500 2022 winners and losers: energy, tech lead the way": 0.5, "All 30 Dow stocks rise, led by Disney and Apple, the previous session\u2019s worst performers": 0.7, "Want to Collect a Dividend Every Month Next Year? Buy These 3 High-Yielding Stocks": 0.7, "Merck &amp; Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 71% Above Its Share Price": 0.8, "15 Best Performing Dow Stocks in 2022": 0.7, "12 Best Biotech Stocks to Buy Under $10": 0.7, "Merck (NYSE:MRK) shareholders have earned a 19% CAGR over the last five years": 0.8, "Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer": 0.7, "15 Biggest Companies That Offer Pensions": 0.5, "Meta Settles Cambridge Analytica Scandal Case, Microsoft Files Rebuttal To FTC's Lawsuit Against Activision Deal, US Winter Storm Snaps Holiday Plans: Today's Top Stories": 0.5, "Merck COVID Antiviral Does Not Reduce Risk Of Hospitalization, Death Rates In Vaccinated Individuals": 0.0, "12 Most Advanced Countries in Science": 0.5, "12 Best Performing Dividend Stocks in 2022": 0.7, "Merck's COVID pill does not cut hospitalisation, death rates in many vaccinated adults - study": 0.0, "Merck, Kelun-Biotech Ink Licensing Pact For Seven Cancer Candidates": 0.5, "Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billion": 0.5, "Why Many Cold Medicines Don\u2019t Work to Relieve Congestion": 0.5, "Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference": 0.5, "Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer": 0.5, "7 Drug Stocks That Will Soar in 2023": 0.7, "7 Perfect Presents to Gift Your 2023 Stock Portfolio": 0.7, "12 Most Advanced Countries in Biotechnology": 0.5, "After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm": 0.2, "Merck Video: What the \u201cGreat Resignation\u201d Taught Us About Workplace Culture": 0.5, "Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings": 0.5, "LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer": 0.5, "Possible bearish signals as Merck &amp; Co., Inc. (NYSE:MRK) insiders disposed of US$3.0m worth of stock": 0.2, "Top M&amp;A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says": 0.8, "Moderna builds out upper management with new commercial SVP": 0.6, "Merck's Stock Could Keep Climbing Higher": 0.7, "Dividend Achievers List Ranked By Yield: Top 25": 0.5, "Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer": 0.7, "Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer": 0.7, "Are These Multibillion-Dollar Vaccine Stocks Still a Buy?": 0.5, "Is Merck &amp; Co., Inc. (NYSE:MRK) Trading At A 43% Discount?": 0.4, "Coinbase, Moderna, Tesla: Stocks That Defined the Week": 0.5, "Merck Leaders Recognized As Influential Women Executives": 0.6, "15 Biggest Endowments in the US and Their Investments": 0.5, "BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities": 0.7, "Company News for Dec 15, 2022": 0.5, "Elon Musk Dumps Another $3.6B Tesla Stock, Facebook's Jobs' Feature To Disappear Next Year, Foxconn Relaxes Covid Restrictions In China Factory: Today's Top Stories": 0.4, "2 Dividend Stocks to Buy and Hold Through 2023 and Beyond": 0.6, "West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies": 0.7, "The Best ETF For Dividend Yield And Dividend Growth": 0.6, "AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer": 0.6, "FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza": 0.4, "7 Stocks to Buy on the Dip as the S&amp;P 500 Falters": 0.5, "J&amp;J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies": 0.7, "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick": 0.6, "12 Best Blue Chip Stocks That Outperformed in 2022": 0.6, "Midday movers: Delta Air Lines, Aspen Group, Charter Communications and more": 0.5, "Moderna, Merck stocks boosted amid joint cancer vaccine trials": 0.7, "16 Best Dividend Stocks of 2022": 0.6, "The 7 Best Investment Funds to Navigate a Possible Recession": 0.6, "Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says": 0.7, "Personalized cancer vaccine results are a 'home run': Moderna CEO": 0.8, "11 Best Low Beta Stocks to Buy": 0.6, "Moderna\u2019s mRNA Cancer Vaccine Shows Promise in Preliminary Study": 0.7, "Why Moderna Stock Is Skyrocketing Today": 0.8, "5 Dow Stocks That Helped the Index Minimize Loss in 2022": 0.6, "Moderna and Merck\u2019s cancer vaccine trial shows promising initial results": 0.7, "Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps": 0.8, "Midday movers: Moderna, United Airlines, Pinterest and more": 0.6, "Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patients": 0.7, "Why Investors Shouldn't Be Surprised By Merck &amp; Co., Inc.'s (NYSE:MRK) P/E": 0.5, "Moderna, Merck cancer vaccine combo cut melanoma recurrence by 44% - study": 0.7, "Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial": 0.8, "Indonesia to produce Merck's HPV vaccines to combat cervical cancer": 0.6, "10 Best Performing Healthcare ETFs in 2022": 0.6, "Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.": 0.6, "The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere": 0.6, "Amgen secures $28.3 billion deal to buy Horizon Therapeutics": 0.9, "Sanofi shares rise after French drugmaker ditches Horizon deal talks": 0.7, "3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023": 0.8, "Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers &amp; Deere": 0.5, "Here's Why Merck (MRK) is a Strong Value Stock": 0.8, "Here's What We Like About Merck's (NYSE:MRK) Upcoming Dividend": 0.7, "10 Best Halal Dividend Stocks To Buy": 0.7, "Why Shares of Mirati Therapeutics Fell Wednesday": 0.2, "GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial": 0.6, "3 High-Yielding Stocks That Are Up 27%-Plus This Year": 0.8, "4 Defensive Stocks to Prepare Your Portfolio for a Recession": 0.5, "Merck &amp; Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 76%": 0.7, "Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy": 0.8, "Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients": 0.7, "The Zacks Analyst Blog Highlights Caterpillar, Merck, UnitedHealth Group and Walmart": 0.6, "In case you missed it, 6 big dividend hikes: Owens Corning raises by 49%": 0.7, "10 Biggest Issues In the World and The Companies Working on Solving Them": 0.5, "Merck (NYSE:MRK) Is Increasing Its Dividend To $0.73": 0.7, "Should Investors Consider These 3 Low-Beta Stocks?": 0.5, "In Burkina Faso, a Personal Mission To Make a Difference in One Community": 0.6, "Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December": 0.7, "First Patients Dosed in Phase I/II Trial of Enlivex\u2019s Off-the-Shelf Cell Therapy Candidate, AllocetraTM": 0.6, "Merck &amp; Co., Inc.'s (NYSE:MRK) Stock Is Going Strong: Is the Market Following Fundamentals?": 0.7, "FOCUS-Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot": 0.6, "Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors": 0.7, "3 Stocks to Watch That Recently Announced Dividend Hikes": 0.7, "Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting": 0.6, "Horizon Therapeutics Fields Takeover Interest From Pharma Giants": 0.6, "Merck Announces First-Quarter 2023 Dividend": 0.7, "At All-Time Highs, Merck's Stock Is Nearing a Cliff": 0.4, "The New Generation Making an Impact on HIV": 0.6, "FOCUS-Rare success for Alzheimer's research unlocks hope for future therapies": 0.8, "3 Dow Stocks to Take Seriously in 2023": 0.7, "Rallying Merck Stock Flashing Historically Bullish Signal": 0.8, "Should Value Investors Buy Innoviva (INVA) Stock?": 0.5, "Merck &amp; Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?": 0.7, "Merck &amp; Co., Inc. (NYSE:MRK) insiders sold US$3.0m worth of stock, a possible red flag that's yet to materialize": 0.4, "11 Best Diabetes Stocks To Buy Now": 0.7, "15 Best Dividend Stocks of All Time": 0.7, "13 dividend hikes to watch for this week: McCormick, Merck": 0.7, "6 biggest deal reports this week: Manchester United open to selling the club": 0.5, "Are Robust Financials Driving The Recent Rally In Merck &amp; Co., Inc.'s (NYSE:MRK) Stock?": 0.7, "3 Biotech Stocks Smart Investors Should Be Buying Up Now": 0.8, "7 Stocks on the Perfect 10 List": 0.7, "Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal": 0.7, "The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck &amp; Co": 0.6, "Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month": 0.7, "Encompass Health (EHC) Proposes 50-Bed Hospital in Florida": 0.6, "Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck": 0.9, "10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head &amp; Neck Cancer Patients": 0.9, "Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients": 0.8, "Buy These 5 Corporate Giants Flying High in Disappointing 2022": 0.7, "UPDATE 1-Merck's combination cancer therapy succeeds in late-stage study": 0.8, "Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma": 0.8, "Japan Approves First Homegrown Covid-19 Antiviral Pill": 0.7, "AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag": 0.6, "These 10 Stocks are Skyrocketing Today": 0.8, "Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug": 0.5, "As Tesla Sinks to 2-Year Lows, This Nasdaq Stock Just Doubled": 0.7, "Merck to buy Imago BioSciences for $1.35 billion": 0.8, "Is Merck &amp; Co. (MRK) Outperforming Other Medical Stocks This Year?": 0.6, "Cancer-Focused Imago BioSciences Shares Soar After Merck Deal": 0.9, "Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer": 0.8, "UPDATE 1-Drugmaker Merck to acquire Imago BioSciences for $1.35 bln": 0.8, "Imago BioSciences stock soars after Merck bids more than 100% premium to buy the biotech": 0.9, "Merck to buy Imago for $1.35 billion to broaden portfolio of blood disorder drugs": 0.8, "Merck to Acquire Imago BioSciences, Inc.": 0.8, "Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference": 0.7, "Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters": 0.7, "Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall": 0.6, "Merck &amp; Co., Inc.'s (NYSE:MRK) high institutional ownership speaks for itself as stock continues to impress, up 6.4% over last week": 0.7, "The 25 Best Stocks to Buy for Retirement": 0.7, "2 Top Biotech Stocks to Buy Right Now": 0.8, "3 Bargain Stocks You Can Buy Today and Hold Forever": 0.7, "Billionaire Cliff Asness\u2019 Top 10 Dividend Stocks": 0.8, "Credit Suisse Believes In This Pharma Giant's Low Risk Growth Against Uncertain Backdrop": 0.7, "Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval": 0.8, "Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial": 0.6, "Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?": 0.7, "Novartis (NVS) Reportedly Looking to Sell Its Business Units": 0.6, "How Long Can This Top Stock Continue Defying the Bear Market?": 0.7, "4 Reasons to Buy This Hybrid of a Growth and Income Stock": 0.7, "Climate Change: How It's Affecting Your Health and How Businesses Can Help Fight This Global Crisis": 0.6, "Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances": 0.7, "FTX Contagion Spreads To Hong Kong Exchange, Microsoft Outlines New Harassment Policies, Netflix Subscribers Can Terminate Freeloading Account Access: Top Stories Wednesday, Nov. 16": 0.5, "Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says": 0.3, "Merck &amp; Co., Inc.'s (NYSE:MRK) Stock Has Fared Decently: Is the Market Following Strong Financials?": 0.7, "Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective": 0.3, "7 Value Stocks to Buy Before They Pop Off": 0.7, "AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use": 0.8, "AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod": 0.8, "Dividend Kings List by Yield: Top 25 Stocks": 0.8, "European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs": 0.8, "The Zacks Analyst Blog Highlights Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy": 0.7, "LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer": 0.9, "Those who invested in Merck (NYSE:MRK) five years ago are up 118%": 0.8, "Here is Why Growth Investors Should Buy Merck (MRK) Now": 0.7, "15 Best Consistent Dividend Stocks to Buy": 0.8, "Are Investors Undervaluing Innoviva (INVA) Right Now?": 0.5, "Wall Street Cheers Soft Inflation Data: 5 Growth Picks": 0.8, "SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients": 0.7, "AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up": 0.8, "Our Partnerships Help Make Vaccines Accessible Worldwide": 0.7, "Is Merck Too Dependent on Keytruda?": 0.4, "Merck &amp; Co., Inc. (MRK) Hit a 52 Week High, Can the Run Continue?": 0.6, "7 No-Brainer Retirement Stocks to Buy for 2023 and Beyond": 0.8, "Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top": 0.4, "Insiders at Merck &amp; Co., Inc. (NYSE:MRK) sold US$2.8m worth of stock, possibly indicating weakness in the future": 0.3, "The Zacks Analyst Blog Highlights Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage": 0.6, "Top Research Reports for Merck, ConocoPhillips &amp; Adobe": 0.6, "AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?": 0.5, "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick": 0.7, "Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL\u00ae in Systematic Literature Review of 138 Studies": 0.8, "Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil": 0.6, "Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss": 0.3, "Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss": 0.5, "Merck &amp; Co., Inc.'s (NYSE:MRK) P/E Still Appears To Be Reasonable": 0.6, "Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook": 0.4, "Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3": 0.6, "Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss": 0.5, "Dedicated To Developing Women Leaders": 0.7, "This Is the Best Time to Buy These 10 Long-Term Dividend Stocks": 0.8, "The Zacks Analyst Blog Highlights Caterpillar, JPMorgan Chase, Home Depot and Merck &amp; Co": 0.6, "Lilly (LLY) Beats on Q3 Earnings &amp; Sales, Lowers '22 View": 0.7, "4 Blue-Chip Stocks to Buy as Dow Seals Record October Gains": 0.8, "Veeva and Merck Form Long-Term Strategic Partnership": 0.7, "Got $3,000? Here Are 3 Stocks to Buy and Hold for the Long Term": 0.7, "Drugmakers Fight Over Lucrative Pneumonia Vaccines": 0.4, "Merck (MRK) Upgraded to Buy: Here's Why": 0.8, "Merck Is Coming for Pfizer\u2019s Pneumonia Vaccine Market Share": 0.7, "Bristol Myers Touts Positive Reblozyl Data From Late-Stage Blood Disorder Study": 0.8, "Do Merck's (NYSE:MRK) Earnings Warrant Your Attention?": 0.6, "Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia Vaccines": 0.4, "10 Best Vaccine Stocks To Buy Now": 0.8, "Merck &amp; Co., Inc. stock performance and analyst projections": "0.5", "Gilead (GILD) Q3 Earnings &amp; Sales Top, Guidance Raised": 0.8, "Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod": 0.6, "Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?": 0.5, "Merck &amp; Co. (MRK) Q3 2022 Earnings Call Transcript": 0.6, "Merck (MRK) Beats on Q3 Earnings &amp; Revenues, Ups 2022 View": "0.9", "Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a \u2018Blue Wave\u2019": "0.1", "Merck &amp; Co. Breaks Out on the Upside": "0.8", "Merck Lifts Outlook After Quarterly Sales Rise 14%": "0.8", "Merck Clocks More Than 50% Drop In COVID-19 Treatment Sales, Revises Annual Guidance": "0.1", "Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost": "0.9", "Merck (MRK) Q3 Earnings and Revenues Surpass Estimates": "0.8", "UPDATE 3-Merck lifts full-year forecast as Keytruda sales soar": "0.9", "Merck &amp; Co., Inc.'s (NYSE:MRK) large institutional owners must be happy as stock continues to impress, up 5.5% over the past week": "0.8", "Merck stock rises after profit and sales beat, raised outlook": "0.8", "Merck lifts full-year forecast as Keytruda sales soar": "0.9", "Merck Announces Third-Quarter 2022 Financial Results": "0.8", "Merck's CEO to succeed Ken Frazier as chairman": "0.5", "Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck": "0.5", "Merck Shuffles Board Chairmen": "0.5", "Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD &amp; More": "0.5", "10 Best Dow Jones Dividend Stocks that Hedge Funds Love": "0.8", "Is Merck Moving Toward Another Blockbuster Drug Launch?": "0.5", "UPDATE 1-Merck to donate Ebola vaccine candidate for research program in Uganda": "0.8", "10 Best European Dividend Stocks to Buy Now": "0.8", "Merck (MRK) to Report Q3 Earnings: What's in the Cards?": "0.5", "7 Stocks to Sell Before They Give Back This Year\u2019s Gain": "0.1", "European Commission Expands Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents": "0.8", "Merck's Antiviral Therapy Shows Efficacy In Prevention of Cytomegalovirus In Kidney Transplant Patients": "0.8", "Here's Why We Think Merck (NYSE:MRK) Is Well Worth Watching": "0.8", "Merck\u2019s PREVYMIS\u2122 Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation": "0.8", "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth": "0.5", "Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline": "0.1", "15 Biggest Dow Companies By Market Cap": "0.5", "15 Best Drug Stocks to Buy Now": "0.8", "Merck Recognized on Fortune's 2022 Change the World List for Expanding Access to HPV Vaccines": "0.8", "Merck's (NYSE:MRK) five-year earnings growth trails the decent shareholder returns": "0.5", "Merck Outlicenses Two Preclinical TB Candidates To Bill &amp; Melinda Gates Research Institute": "0.8", "Will This News Send Moderna's Stock Soaring?": "0.5", "Merck Animal Health Launches Sure Petcare Animo\u00ae GPS": "0.8", "Merck and the Bill &amp; Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates": "0.8", "Why star-studded Peninsula biotech NGM Biopharmaceuticals saw its stock fall more than 70%": "0.1", "Moderna CEO: Merck deal \u2018could be a game changer\u2019 for cancer treatment": "0.9", "Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24": "0.5", "Merck's (NYSE:MRK) five-year earnings growth trails the 12% YoY shareholder returns": "0.5", "The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK": "0.5", "Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab": "0.9", "Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab": "0.5", "10 Best Fundamental Penny Stocks To Invest In": "0.8", "These 2 Stocks Gave Investors a Nice Surprise Wednesday": "0.8", "Moderna and Merck enter joint venture to develop cancer vaccine": 0.5, "Stock Market Today: Dow Ends Lower as Fed Fears Overshadow Pop in Pepsi": 0.0, "Moderna Jumps as Merck Extends Partnership on Cancer Vaccine": 0.8, "Why Moderna Stock Is Bolting Higher Today": 0.7, "Moderna, Merck to jointly develop cancer vaccine": 0.5, "10 Best Cancer Stocks to Buy Now": 0.7, "Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact": 0.8, "Moderna Stock Surges On Cancer Vaccine Development Pact With Merck": 0.8, "Merck, Moderna to develop personalized cancer vaccine": 0.5, "UPDATE 1-Merck opts to jointly develop cancer vaccine with Moderna": 0.5, "Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine": 0.7, "Health Canada Approves KEYTRUDA\u00ae (pembrolizumab) as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions": 0.5, "3 Dividend Stocks in Warren Buffett's Secret Portfolio Most Likely to Soar in Q4": 0.7, "Moderna Shares Jump After Cancer Vaccine Announcement": 0.7, "Moderna Stock Jumps After Cancer Vaccine Announcement": 0.7, "Merck (MRK) Gains As Market Dips: What You Should Know": "0.6", "IBD 50 Stocks To Watch: Dow Jones Leader Merck Approaches Buy Point": 0.7, "Merck\u2019s Patent Cliff Doesn\u2019t Look So Frightening Anymore": 0.8, "Merck Collaborates Ginkgo Bioworks to Improve Active Pharmaceutical Ingredient Manufacturing": 0.7, "Merck (MRK) Posts Positive Results From PAH Drug Study": 0.8, "12 Best Ethical Stocks To Buy Now": 0.7, "Merck &amp; Co., Inc.'s (NYSE:MRK) large institutional owners must be happy as stock continues to impress, up 3.3% over the past week": 0.7, "Merck hires local synbio player for cell manufacturing": 0.7, "Centre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trial": 0.8, "Merck Recognized on Fortune\u2019s 2022 Change the World List for Expanding Access to HPV Vaccines": 0.8, "UPDATE 2-Merck's blood vessel disorder drug succeeds in late-stage study": 0.8, "Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)": 0.8, "Rivian, Ford Shares Slide Premarket; Toast, Fortinet Rise": 0.0, "3 Great Dividend Stocks to Buy in October": 0.7, "11 Best Long-Term Stocks To Buy Now": 0.7, "With 75% ownership, Merck &amp; Co., Inc. (NYSE:MRK) boasts of strong institutional backing": 0.8, "UK Study Shows Merck's COVID-19 Antiviral Pill Did Not Cut Hospitalization Risk": 0.0, "Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO\u2122 (molnupiravir)": 0.5, "Is Merck &amp; Co. (MRK) a Good Long-Term Investment?": 0.7, "GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal": 0.8, "Top 20 Drug Companies in the World in 2022": 0.5, "AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial": 0.8, "Is Exelixis' (EXEL) Growth Story Likely to Continue?": 0.5, "Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy": 0.5, "10 Healthcare Stocks to Watch in Light of Biden\u2019s \u201860 Minutes\u2019 Interview": 0.7, "10 Best Diversified Dividend Stocks to Buy Now": 0.7, "Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?": 0.5, "What This News Means for Merck": 0.5, "U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit": 0.7, "Merck wins ruling upholding diabetes-treatment patent at U.S. appeals court": 0.7, "Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China": 0.5, "Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27": 0.5, "11 Best Dividend Paying Stocks To Buy Now": 0.9, "Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China": 0.7, "Merck's (MRK) Keytruda Gets Four New Approvals in Japan": 0.8, "10 High Dividend Stocks Picked by Billionaire Gabelli": 0.9, "Bear Market: 2 Safe Stocks to Buy Right Now": 0.7, "7 Blue-Chip Sleeper Stocks to Buy Before Wall Street Wakes Up": 0.9, "Atea (AVIR) Dengue Candidate Gets Fast Track Designation": 0.8, "Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head &amp; Neck Cancer": 0.7, "Merck Animal Health Completes Minority Investment in LeeO Precision Farming": 0.6, "Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)": 0.8, "7 Dow Sleeper Stocks to Buy Before Wall Street Wakes Up": 0.9, "Dow Jones ETF Avoids Bear Market: 4 Stocks in Green": 0.8, "10 Best Biotech Stocks Under $10": 0.9, "11 Best Defensive Stocks For An Upcoming Crash": 0.9, "Recession Fears Save Pharma From Drug-Pricing Concerns": 0.7, "A Stock's Price \"Tells You Almost Nothing\"": 0.5, "Merck (NYSE:MRK) shareholders have earned a 11% CAGR over the last five years": 0.8, "Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris": 0.7, "Pharma Stock Roundup: EU Nod to AZN &amp; RHHBY Drugs, FDA Updates for LLY &amp; MRK": 0.7, "10 Most Shorted Stocks in September": 0.5, "My Take: 4 Strong Growth Stocks to Buy This Week": 0.8, "Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings": 0.7, "Here\u2019s Why You Should Consider Acquiring Merck (MRK) Shares": 0.8, "Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study": 0.7, "Merck Animal Health to Acquire Vence": 0.7, "Nanobiotix Establishes Recommended Dose For Registrational Study Of Head &amp; Neck Combo Therapy Trial": 0.7, "LYNPARZA\u00ae (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer": 0.8, "U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit": 0.7, "Quant Billionaire Jim Simons Loves These 10 Defensive Stocks": 0.9, "Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose": 0.7, "3 Best Dow Jones Stocks of 2022 So Far: Are They Buys Now?": 0.8, "Merck (MRK) Stock Moves -0.74%: What You Should Know": 0.4, "3 Stocks That Could Rocket on Biden\u2019s Cancer Moonshot": 0.8, "Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold": 0.7, "Here's Why Merck (NYSE:MRK) Has Caught The Eye Of Investors": 0.8, "Mohamed El-Erian Says Stagflation Is Coming; Here Are 2 \u2018Strong Buy\u2019 Dividend Stocks to Protect Your Portfolio": 0.9, "UPDATE 1-Merck to start studying lower dose of HIV drug after FDA hold": 0.7, "Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection": 0.7, "Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids": 0.7, "The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca": 0.7, "7 Penny Stocks That Actually Have a Buy Rating": 0.8, "7 Undervalued Stock Picks to Beat the September Market Slump": 0.9, "4 Large Drug Stocks to Watch as Fundamentals Stay Strong": 0.8, "Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children": 0.7, "Why This Monster Stock's Recent Blunders Might Not Matter": 0.5, "2 Healthcare Stocks That Could Help Set You Up for Life": 0.8, "The Zacks Analyst Blog Highlights Merck, Cisco, Morgan Stanley, CME Group and Canadian Natural Resources": 0.5, "7 Small-Cap Stock Picks to Beat the September Market Slump": 0.7, "Top Analyst Reports for Merck, Cisco &amp; Morgan Stanley": 0.5, "Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why": 0.6, "Key Factors Driving Merck's (MRK) Outperformance This Year": 0.6, "10 Dividend Stocks to Buy According to Billionaire Cliff Asness": 0.7, "Immutep Issues Development Update For Its Lead Cancer Candidate": 0.5, "Merck (MRK) is a Top-Ranked Value Stock: Should You Buy?": 0.6, "AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&amp;D investments, analysts say": 0.7, "Alphabet, Nucor, Bristol-Myers Squibb Fall Premarket; Starbucks Rises": 0.4, "After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff": 0.2, "Health Canada Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection": 0.6, "Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer": 0.5, "Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer": 0.5, "Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer Patients": 0.6, "Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer": 0.4, "Top 5 Things to Watch in Markets in the Week Ahead": 0.5, "Five-Year Data for Merck's KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)": 0.6, "Top 10 Stock Picks of John Zaro\u2019s Bourgeon Capital": 0.7, "Why You Might Be Interested In Merck &amp; Co., Inc. (NYSE:MRK) For Its Upcoming Dividend": 0.5, "Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma": 0.6, "AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer": 0.6, "LYNPARZA\u00ae (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials": 0.6, "Merck (MRK) Gains But Lags Market: What You Should Know": 0.5, "The Petri Dish: Homology gets new CEO amid shakeup; two Boston firms join 'pandemic readiness' lobby": 0.5, "Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer Care": 0.7, "Connecting Employees With NGOs for Impactful 3-Month Assignments": 0.5, "Merck, Eli Lilly back new Longwood Fund startup that aims to control proteins": 0.6, "Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate": 0.5, "10 Best Cheap Stocks to Buy Now": 0.7, "Target CEO Brian Cornell to Stay Three More Years": 0.5, "Merck's Deal With Seagen May Have Fallen Through. Now What?": 0.4, "Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference": 0.5, "25 Biggest Pharmaceutical Companies in the World A Year Ago": 0.5, "10 Best Blue Chip Stocks To Buy": 0.7, "Merck (MRK) Stock Moves -1.06%: What You Should Know": 0.4, "Long-Term Analyst: Don\u2019t Play the \u201cFool\u2019s Game\u201d of Timing the Market and Buy These 10 Stocks": 0.6, "3 Stocks to Buy in September as the Market Falls and Rates Rise": 0.8, "Advancing Health Equity Through Impact Investing": 0.9, "Novartis Appoints Merck Executive As Research Head": 0.5, "India develops its first cervical cancer vaccine": 0.7, "Why Guardant Health Crushed the Market Today": 0.9, "U.S. plans to move COVID vaccines, treatments to private markets in 2023": 0.4, "Merck Reports Strong Progress in ESG Focus Areas": 0.8, "With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report": 0.3, "10 Best Dividend Stocks to Buy According to Israel Englander\u2019s Millennium Management": 0.7, "Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer": 0.8, "Merck\u2019s Talks to Acquire Seagen Hit Snag Over Price": 0.4, "Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?": 0.5, "Merck's Buyout Of Seagen Hits Speed Braker Over Price Agreement: Report": 0.4, "Cross-Sector: Market Data Highlights": 0.5, "Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?": 0.5, "J&amp;J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli": 0.7, "AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs": 0.6, "Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass": 0.5, "Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments": 0.7, "LYNPARZA\u00ae (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer": 0.7, "Merck invests in radiopharmaceuticals startup's $84M round": 0.6, "Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy": 0.7, "Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down": 0.5, "Should Income Investors Buy This Dividend Stock?": 0.6, "Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy": 0.7, "Sound Shore Management: \u201cMerck &amp; Co. (MRK) Remains Attractive at Less Than 12 Times 2023 Earnings\u201d": 0.8, "FDA Says Study Needed To Assess Another Round Of Pfizer's COVID-19 Pill As Infection Rebounds": 0.4, "Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments": 0.7, "Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK": 0.5, "10 Large-Cap Dividend Stocks with Over 5% Yield": 0.7, "Merck Receives Dual Recognition As Top 50 Best Companies for Latinas and Top Hispano-Latino EBRG": 0.8, "What's in the Cards for Medtronic (MDT) in Q1 Earnings?": 0.5, "10 Small-Cap Stocks that Pay Dividends": 0.7, "Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial": 0.8, "The Story of the Greatest Mom and Pop Investor Ever": 0.6, "Here\u2019s What Makes Merck &amp; Co. (MRK) a Good Investment Choice": 0.8, "Merck (MRK) Enters Into Circular RNA Collaboration With Orna": 0.6, "Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids": 0.6, "Merck strikes $3.5B collab with local RNA startup, invests in $221M Series B": 0.7, "Merck, Orna Therapeutics sign circular RNA collaboration deal valued at up to $3.65B": 0.7, "3 Top Stocks to Invest In Right Now": 0.8, "Here's Why You Should Retain Thermo Fisher (TMO) Stock Now": "0.5", "Why Moderna Stock Is Sliding Today": 0.4, "Merck Bets $250M On Next-Gen Approach To mRNA For Infectious Diseases, Cancer": 0.7, "Merck Jumps Into a $3.7 Billion mRNA Collaboration": 0.7, "Merck and Orna Therapeutics to collaborate in deal entitling Orna to up to $3.5 billion in milestone payments": 0.7, "FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review": 0.7, "Merck and Orna Therapeutics Collaborate to Advance Orna\u2019s Next Generation of RNA Technology": 0.8, "AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use": 0.7, "Is Merck &amp; Co. (MRK) a Great Investment Pick?": 0.6, "10 Important Dividend Increases to Watch in August": 0.5, "Biotech Keeps Staving Off the Bear, but for How Long?": 0.4, "Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View": 0.2, "10 Famous Value Stocks that Underperformed in 2022": 0.3, "Seagen Suffers Loss In Arbitration Dispute Over ADC Technology": 0.2, "National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut": 0.5, "10 Healthcare Stocks to Watch Amid Senate\u2019s Healthcare Bill": 0.5, "ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up": 0.7, "Senate Finance Committee Expands Amgen's Tax Probe: Report": 0.3, "J&amp;J (JNJ) to Stop Selling Talc-based Baby Powder From 2023": 0.2, "STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays": 0.6, "Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up": 0.7, "Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe": 0.4, "Experts Discuss Importance of Cancer Screenings and Early Detection": 0.6, "Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down": 0.2, "Is it a Good Choice to Invest in Merck &amp; Co. (MRK)?": 0.6, "Biotech Startup Cerevance Strikes Alzheimer\u2019s Research Deal With Merck": 0.8, "10 defensive stocks that can also provide you with growth and dividends over the long term": 0.5, "SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut": 0.2, "10 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat": 0.5, "To Avoid Supply Crunch, FDA Temporarily Allows Higher Impurity Levels In Merck's Diabetes Drug: Report": 0.3, "Immunology startup GentiBio signs $1.9B deal with Bristol Myers": 0.7, "Get ready for more merger mania in pharma sector the rest of the year": 0.6, "Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe &amp; McDonald's": 0.5, "Merck Re-enters Alzheimer's R&amp;D With Research Pact With Cerevance": 0.7, "Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up": 0.4, "Chronic cough drug developer plays it cool as it seeks cash for late-stage study": 0.5, "The Zacks Analyst Blog Highlights Exxon Mobil, Merck &amp; Co, Chevron, American Electric Power and The Southern": 0.5, "Markets close mixed, meme stocks accelerate gains": 0.5, "NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat": 0.4, "Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern": 0.3, "These 3 Dow Stocks Are Set to Soar in 2022's Second Half and Beyond": 0.7, "10 Dividend Stocks to Buy According to Steve Cohen\u2019s Point72 Asset Management": 0.5, "5 High-Flying U.S. Corporate Giants to Buy Despite Volatility": 0.6, "2 Healthcare Stocks You Can Buy and Hold for the Next Decade": 0.7, "Merck defends tax approach against senator\u2019s claims of avoidance": 0.4, "Amgen says Lumakras plus immunotherapy for lung cancer needs further study": 0.3, "3 Great Stocks to Buy in August for Safety and Long-Term Growth": 0.7, "Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down": 0.4, "How We're Supporting the Advancement of Women of Color at Our Company": 0.6, "Pharmaceutical CEOs use earnings calls to criticize drug-pricing proposal": 0.3, "12 Best Healthcare Stocks To Buy Now": 0.7, "Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View": 0.4, "Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down": 0.3, "Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut": 0.2, "LYNPARZA\u00ae (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer": 0.7, "Here\u2019s Why You Should Consider Investing in Merck &amp; Co. (MRK)": 0.6, "CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down": 0.4, "Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down": 0.6, "Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut": 0.5, "STERIS (STE) Q1 Earnings Match Estimates, EPS View Down": 0.4, "Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal": 0.0, "Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma": 0.5, "Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer": 0.5, "Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?": 0.2, "Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up": 0.7, "Stocks lower at open, Caterpillar stock falls, gold hits 4-week high": 0.2, "We Ran A Stock Scan For Earnings Growth And Merck (NYSE:MRK) Passed With Ease": 0.6, "Looking for a Growth Stock? 3 Reasons Why Merck (MRK) is a Solid Choice": 0.7, "Merck (MRK) Upgraded to Buy: Here's What You Should Know": 0.7, "Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment": 0.6, "Health care bill \u2018most aggressive action\u2019 on drug pricing: Analyst": 0.3, "The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca": 0.5, "U.S. Would Gain Power to Negotiate Drug Prices Under Manchin-Schumer Bill": 0.4, "Seagen's (SGEN) Earnings &amp; Revenues Surpass Estimates in Q2": 0.6, "Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings &amp; Sales Beat, GSK Results Mixed": 0.5, "AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View": 0.6, "Apple and Amazon\u2019s Tech Strength Gets Bulls Buying Despite Recession on the Radar": 0.7, "Merck &amp; Co. (MRK) Q2 2022 Earnings Call Transcript": 0.5, "Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit": 0.2, "Merck (MRK) Q2 Earnings &amp; Revenues Top, COVID Drug Helps Sales": 0.7, "Alkermes' (ALKS) Earnings &amp; Revenues Surpass Estimates in Q2": 0.6, "Manchin Deal Lifts Odds of Drug-Price Overhaul. Pharma Stocks Might Be Unscathed.": 0.5, "Merck Tops Profit Estimates on Strong Keytruda and Gardasil Sales": 0.7, "UPDATE 1-Merck profit tops Wall Street view on strong Keytruda sales": 0.7, "Merck, Pfizer stocks under pressure after reporting earnings": 0.3, "Pfizer Earnings Beat Expectations. Vaccine and Paxlovid Sales Were Higher Than Anticipated.": 0.7, "Merck Joins Novartis-Led Collaboration To Increase Diversity in Clinical Trials": 0.6, "7 Stocks to Buy on the Dip": 0.7, "Keytruda, Gardasil Boost Merck's Q2 Revenues, Tightens Annual Guidance": 0.7, "Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates": 0.7, "Merck profit tops Wall Street view on strong Keytruda sales": 0.7, "Merck Announces Second-Quarter 2022 Financial Results": 0.5, "Merck quarterly profit tops Wall Street view on strong Keytruda sales": 0.7, "Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE &amp; More": 0.5, "Stocks: Tech leads gains, home builders fall, Sherwin-Williams sinks": 0.4, "Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator": 0.2, "7 Dividend Stocks to Buy on the Dip": 0.7, "Merck Announces Fourth-Quarter 2022 Dividend": 0.5, "Market check: Walmart warnings drags retail stocks down": 0.3, "Drugmakers Hope New Heart Drugs Boost Sales, Revive Market": 0.5, "Seagen shares positive data for bladder cancer drug; stock is up 2.5%": 0.6, "Seagen Shares Jump On Positive Data From Urothelial Cancer Trial": 0.6, "Investment banker, ex-FBI trainee charged with insider trading": "0.0", "Merck (MRK) to Report Q2 Earnings: What's in the Cards?": "0.5", "These 10 Companies Recently Increased Their Dividends": "0.8", "The Zacks Analyst Blog Highlights J&amp;J, Novartis, GSK, Merck and AbbVie": "0.5", "Top 5 Things to Watch in Markets in the Week Ahead - Fed Rate Hike, Earnings Flood": "0.5", "Merck Q2 Preview: Double-Digit Earnings Growth in Store?": "0.6", "Merck Continues to Look Like a Slow but Steady Long Bet": "0.6", "Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie": "0.7", "5 Cheap Healthcare Stocks in 2022": "0.8", "Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View": "0.7", "10 Best Dividend Stocks of All Time": "0.8", "Is a Beat Likely for F5 Networks (FFIV) This Earnings Season?": "0.5", "Merck's (MRK) Keytruda Head and Neck Cancer Study Fails": "0.0", "Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up": "0.7", "LabCorp (LH) to Offer New Test Report for Venom Allergy Testing": "0.5", "AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use": "0.7", "Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab": "0.5", "10 Best Long-Term Dividend Stocks": "0.8", "'We Are Encouraged To Be Who We Are': An LGBTQ+ Colleague Shares His Story": "0.8", "Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks": "0.5", "What's in the Offing for Infosys (INFY) This Earnings Season?": "0.5", "Merck's Keytruda fails head and neck cancer trial": "0.0", "Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma": "0.5", "Netflix, Omnicom Rise Premarket; Baker Hughes, Merck Fall": "0.4", "Tech and semiconductor stocks move higher into the close, U.S. dollar rally comes to a pause": "0.5", "COVID: CDC unanimously recommends Novavax vaccine for adults": "0.7", "Merck &amp; AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study": "0.0", "Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings": "0.6", "Here's Why You Should Retain Chemed (CHE) Stock For Now": "0.5", "GSK Completes Demerger of Consumer Healthcare Business": "0.5", "Company News for Jul 19, 2022": "0.5", "Align Technology (ALGN) to Post Q2 Earnings: What's in Store?": "0.5", "Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada": "0.7", "AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine": "0.5", "PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors": "0.5", "10 Blue Chip Dividend Stocks with Over 5% Yield": "0.8", "Merck and Block have been highlighted as Zacks Bull and Bear of the Day": "0.5", "Bull of the Day: Merck &amp; Co. (MRK)": "0.5", "10 Stocks Billionaire Ken Fisher May Never Sell": "0.8", "UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View": "0.7", "Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?": "0.5", "Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds": "0.5", "Best Growth Stocks to Buy for July 15th": "0.8", "Best Income Stocks to Buy for July 15th": "0.8", "Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study": "0.5", "Here's Why Investors Should Retain Phibro (PAHC) For Now": "0.5", "LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis": "0.5", "Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate": "0.7", "What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?": "0.5", "Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate": 0.9, "Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?": 0.5, "Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study": 0.7, "6 Dow Stocks to Buy on the Dip": 0.6, "Merck Makes $290M Bet On Prostate Cancer Candidate": 0.8, "CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay": 0.4, "Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises": 0.8, "3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health": 0.7, "The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals": 0.5, "Scientists Get $1 Million Prize to Fight Climate Change With \u2018Photosynthesis 2.0\u2019": 0.9, "Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer": 0.8, "Finnish Pharma Firm Orion Raises Outlook After Merck Agreement": 0.7, "Top Stock Reports for Coca-Cola, Merck &amp; Toyota Motor": 0.5, "Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5": 0.8, "Amgen's Lumakras combination data held for August lung cancer meeting": 0.6, "Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study": 0.7, "Here's Why You Should Retain Walgreens Boots (WBA) For Now": 0.5, "Why You Should Buy Now and Hold This #1 (Strong Buy) Medical Stock": 0.9, "PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents": 0.8, "COVID subvariants: Vaccinated individuals \u2018still at pretty high risk\u2019 of infection, doctor says": 0.2, "Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base": 0.7, "Biotech Stocks Are Up by Double Digits. It\u2019s Still a Bear Market.": 0.4, "Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal": 0.6, "10 Monthly Dividend Stocks with Over 5% Yield": 0.7}